|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | General synthesis of high-performing magneto-conjugated polymer core-shell nanoparticles for multifunctional theranostics显示文摘最近,增加注意作为 theranostic 平台被付了到结合磁电机的聚合物核心壳 nanoparticles (NP ) 。然而,表面活化剂的利用和有在合成的潜在的毒性的额外的氧化剂,为磁性的 NP ( MNP )@的各种各样的类型的控制合成的一般方法的缺乏结合了聚合物 NP ,并且获得平衡磁电机光的性质的困难极大地在 theranostics 限制了结合磁电机的聚合物的应用。我们发展了一在里面没有额外的表面活化剂和氧化剂的 situ 表面聚合方法综合有平衡、突出的磁电机光的性质的 MNP@polypyrrole (PPy ) NP。有一种可调节的尺寸,不同形状,和控制的壳厚度的 MNP@PPy NP 用这个方法被获得。方法被扩大综合另外的结合 MNP 的聚合物核心壳 NP,例如 MNP@polyaniline 并且 MNP@poly (3,4-ethylenedioxythiophene ): poly (4-styrenesulfonate )(PEDOT : PSS ) 。我们根据我们的试验性的结果讨论建议方法的形成机制。最后,使用光并且获得的 MNP@PEDOT 的磁性: PSS NP,在 vivo,多模式的指导成像的过高热在老鼠被导致,完成优秀肿瘤脱离治疗学的效果。我们的工作为在生物医学的域里扩大结合 MNP 的聚合物核心壳 NP 的应用程序是有益的。 | Hao Yan Lingyun Zhao Wenting Shang Zhongqun Liu Wensheng Xie Cai Qiang Zhiyuan Xiong Ranran Zhang Baohua Li Xiaodan Sun Feiyu Kang | 2017 | Nano Research2017，10，2： | 2 |
| 2 | Optical Molecular Imaging Frontiers in Oncology: The Pursuit of Accuracy and Sensitivity显示文摘Cutting-edge technologies in optical molecular imaging have ushered in new frontiers in cancer research, clinical translation, and medical practice, as evidenced by recent advances in optical multimodality imaging, Cerenkov luminescence imaging(CLI), and optical imageguided surgeries. New abilities allow in vivo cancer imaging with sensitivity and accuracy that are unprecedented in conventional imaging approaches. The visualization of cellular and molecular behaviors and events within tumors in living subjects is improving our deeper understanding of tumors at a systems level. These advances are being rapidly used to acquire tumor-to-tumor molecular heterogeneity, both dynamically and quantitatively, as well as to achieve more effective therapeutic interventions with the assistance of real-time imaging. In the era of molecular imaging, optical technologies hold great promise to facilitate the development of highly sensitive cancer diagnoses as well as personalized patient treatment—one of the ultimate goals of precision medicine. | Kun Wang Chongwei Chi Zhenhua Hu Muhan Liu Hui Hui Wenting Shang Dong Peng Shuang Zhang Jiezuo Ye Haixiao Liu Jie Tian | 2015 | Engineering2015，1，3： | 1 |
| 3 | The existence of a nonclassical TCA cycle in the nucleus that wires the metabolic-epigenetic circuitry显示文摘The scope and variety of the metabolic intermediates from the mitochondrial tricarboxylic acid(TCA)cycle that are engaged in epigenetic regulation of the chromatin function in the nucleus raise an outstanding question about how timely and precise supply/consumption of these metabolites is achieved in the nucleus.We report here the identification of a nonclassical TCA cycle in the nucleus(nTCA cycle).We found that all the TCA cycle-associated enzymes including citrate synthase(CS),aconitase 2(ACO2),isocitrate dehydrogenase 3(IDH3),oxoglutarate dehydrogenase(OGDH),succinyl-CoA synthetase(SCS),fumarate hydratase(FH),and malate dehydrogenase 2(MDH2),except for succinate dehydrogenase(SDH),a component of electron transport chain for generating ATP,exist in the nucleus.We showed that these nuclear enzymes catalyze an incomplete TCA cycle similar to that found in cyanobacteria.We propose that the nTCA cycle is implemented mainly to generate/consume metabolic intermediates,not for energy production.We demonstrated that the nTCA cycle is intrinsically linked to chromatin dynamics and transcription regulation.Together,our study uncovers the existence of a nonclassical TCA cycle in the nucleus that links the metabolic pathway to epigenetic regulation. | Xujun Liu Wenzhe Si Lin He Jianguo Yang Yani Peng Jie Ren Xiaoping Liu Tong Jin Huajing Yu Zihan Zhang Xiao Cheng Wenting Zhang Lu Xia Yunchao Huang Yue Wang Shumeng Liu Lin Shan Yu Zhang Xiaohan Yang Haixia Li Jing Liang Luyang Sun Yongfeng Shang | 2021 | Signal Transduction and Targeted Therapy2021，6，12： | 0 |
| 4 | Investigation on the short-term outcome and prognostic impact of predisposition,and precipitants in inpatients with chronic liver disease from Chinese AcuTe on CHronic LIver FailurE(CATCH-LIFE)cohorts显示文摘Aim:The study aimed to investigate the short-term outcomes of hospitalized patients with chronic liver disease(CLDs)and assess the prognostic impact of predisposition and precipitants,which currently remains unclear.Methods:The study included 3970 hospitalized patients with CLDs from two prospective longitudinal multicenter studies(NCT02457637 and NCT03641872)conducted in highly endemic hepatitis B virus(HBV)areas.Competing risk analysis was used to evaluate the effect of predispositions,including the etiology and severity of CLDs and precipitants;on sequential 28,90,and 365-day liver transplantation(LT)-free mortality.Results:Among all enrolled patients,76.8%of adverse outcomes(including death and LT)within one year occurred within 90 days.Compared with alcoholic etiology,the association of HBV etiology with poorer outcomes was remarkably on the 28th day(hazard ratio[HR],1.81;95%confidence interval[CI],1.07-3.06;p=0.026);however,and dimin-ished or became insignificant at 90 days and 365 days.Cirrhosis increased the adjusted risk for 365-day(HR,1.50;CI,1.13-1.99;p=0.004)LT-free mortality when compared with noncirrhosis.In patients with cirrhosis,prior decompensation(PD)independently increased the adjusted risk of 365-day LT-free mortality by 1.25-fold(p=0.021);however,it did not increase the risk for 90-day mortality.Neither the category nor the number of precipitants influenced the adjusted risk of 28 or 90-day LT-free mortality.Conclusions:The 90-day outcome should be considered a significant endpoint for evaluating the short-term prognosis of hospitalized patients with CLD.Predisposing factors,other than etiology,mainly affected the delayed(365-day)outcome.Timely effective therapy for CLD etiology,especially antiviral treatments for HBV,and post-discharge long-term surveillance monitoring in cirrhotic patients undergoing PD are suggested to enhance disease management and reduce mortality. | Yan Zhang Wenting Tan Xiaobo Wang Xin Zheng Yan Huang Beiling Li Zhongji Meng Yanhang Gao Zhiping Qian Feng Liu Xiaobo Lu Jia Shang Yubao Zheng Weituo Zhang Shan Yin Wenyi Gu Tongyu Wang Jianyi Wei Zixuan Shen Guohong Deng Yi Zhou Yixin Hou Qun Zhang Shue Xiong Jing Liu Liyuan Long Ruochan Chen Jinjun Chen Xiuhua Jiang Sen Luo Yuanyuan Chen Chang Jiang Jinming Zhao Liujuan Ji Xue Mei Jing Li Tao Li Rongjiong Zheng Xinyi Zhou Haotang Ren Yu Shi Hai Li for the CATCH‐LIFE Study Investigators of Chinese(Acute‐on)Chronic Liver Failure(CLIF)Consortium(Ch‐CLIFC) | 2023 | Portal Hypertension & Cirrhosis2023，2，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员